US FDA Commissioner’s Involvement In AstraZeneca Pricing Deal Raises Ethical, Legal Questions

 
• By Sarah Karlin-Smith
  
Virginia Gov. Glenn Youngkin, AstraZeneca CEO Pascal Soriot, US President Donald Trump, CMS Administrator Mehmet Oz and FDA Commissioner Marty Makary in White House
US President Donald Trump speaks about an AstraZeneca-government drug pricing deal publicly announced Oct. 10. (White House website)

More from Pricing Debate

More from United States